Apellis Pharmaceuticals, Inc. (APLS) Q1 2018 Earnings Results

Apellis Pharmaceuticals Misses on EPS, Stock Down 3.94%

Apellis Pharmaceuticals reported a loss of $0.43 per share, which was in line with expectations, but the lack of revenue data and guidance contributed to a negative stock reaction, with shares falling by 3.94%. Investors may be concerned about the company's future performance without clear financial targets or updates on revenue generation.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.43	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management emphasized the importance of their clinical pipeline. However, without specific guidance or revenue figures, the outlook remains uncertain.

Management did not provide specific revenue figures or future guidance.

The focus remains on ongoing clinical trials and product development.

Apellis Pharmaceuticals Misses on EPS, Stock Down 3.94%

Key numbers

Management commentary

Apellis Pharmaceuticals, Inc.

More earnings this week

Apellis Pharmaceuticals Misses on EPS, Stock Down 3.94%

Key numbers

Management commentary